Haleon PLC
NYSE:HLN

  • LAST PRICE
    9.5800
  • TODAY'S CHANGE (%)
    -0.0700 (-0.7254%)
  • Bid / Lots
    9.4000/ 1
  • Ask / Lots
    9.7300/ 1
  • Open / Previous Close
    9.5900 / 9.6500
  • Day Range
    9.5500
    9.6500
  • 52 Week Range
    7.8900
    10.8000
  • Volume
    7,638,483

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

  • Oct 31, 2024

      Show headlines and story abstract

    • 8:56AM ET on Thursday Oct 31, 2024 by MT Newswires
      Companies Mentioned: HLN
      08:56 AM EDT, 10/31/2024 (MT Newswires) -- Haleon (HLN) reported Q3 revenue Thursday of 2.78 billion British pounds ($3.61 billion), down from 2.80 billion pounds a year earlier. Three analysts polled by Capital IQ expected 2.85 billion pounds. Reve...

    • 3:57AM ET on Thursday Oct 31, 2024 by Dow Jones

      0757 GMT - Haleon's 3Q results don't surprise as the company backed its full-year outlook and delivered mostly in line with expectations, RBC Capital Markets analysts say in a note. The British consumer-health business's organic revenue growth came in slightly ahead of consensus, at the top end of its 2024 guided range, James Edwardes Jones and Wassachon Udomsilpa write. Its Respiratory Health business grew the most, boosted by expected trade reloading in the U.S. The second-largest grower was its Oral Health, Digestive Health and Other segment, the analysts say. (helena.smolak@wsj.com)

    • 3:00AM ET on Thursday Oct 31, 2024 by Dow Jones

      By Helena Smolak

      Haleon backed its full-year guidance despite lower third-quarter revenue and earnings that fell short off analysts' expectations.

      The British consumer-healthcare business--which was spun out of GSK and is partly owned by Pfizer--said Thursday that revenue for the quarter was 2.78 billion pounds, equivalent to $3.60 billion, compared with 2.80 billion pounds for the prior-year period and a company-compiled analyst consensus of 2.83 billion pounds.

Peers Headlines